Elapegademase: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Elapegademase. Educational only — not medical advice.
Labeled uses
REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
Source: FDA labeling via NIH DailyMed (set 8c073f84…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.